A novel automated SARS-CoV-2 saliva PCR test protects a global asymptomatic workforce.

Autor: Carter N; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK., Clausen M; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Halpin RA; Early Oncology, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Blackmore C; R&D IT, AstraZeneca, Cambridge, UK., Cai K; Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Delpuech O; Early Oncology, Oncology R&D, AstraZeneca, Cambridge, UK., Kohlmann A; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Magnusson O; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., March R; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK., O'Neill D; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK., Prakash K; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Sherwood J; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK., Sundin T; Global Medical Affairs, Oncology Business Unit, AstraZeneca, Gaithersburg, MD, USA., Swift J; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK., Tarakameh A; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Wijdicks M; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK., Wise D; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK., Fidock M; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK. mark.fidock@astrazeneca.com.

Publikováno v: Scientific reports [Sci Rep] 2021 Jun 16; Vol. 11 (1), pp. 12676. Date of Electronic Publication: 2021 Jun 16.